Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A routine part of the process for developing National Institute for Health and Care Excellence (NICE) medical technologies guidance is a submission of clinical and economic evidence by the technology manufacturer. The Birmingham and Brunel Consortium External Assessment Centre (EAC; a consortium of the University of Birmingham and Brunel University) independently appraised the submission on the EXOGEN bone healing system for long bone fractures with non-union or delayed healing. This article is an overview of the original evidence submitted, the EAC's findings, and the final NICE guidance issued.

Original publication





Appl Health Econ Health Policy

Publication Date





477 - 484


Adult, Advisory Committees, Aged, Aged, 80 and over, Cost-Benefit Analysis, Female, Femur, Fibula, Fracture Healing, Fractures, Ununited, Humans, Humerus, Male, Middle Aged, Radius, Technology Assessment, Biomedical, Tibia, Ulna, Ultrasonic Therapy, Ultrasonography, United Kingdom, Young Adult